Multiomics, Rare Cancers
Conditions
Brief summary
NCT/DKFZ/DKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.
Interventions
None listed
Sponsors
German Consortium for Translational Cancer Research
German Cancer Research Center
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Rare cancer (Incidence \<6/100,000 persons/year) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation) Metastatic and/or locally advanced cancer with no curative therapy option and indication for systemic therapy
Exclusion criteria
Severe neurological or psychiatric disorder interfering with the ability to give oral and written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 10 years | time period of survival from date of diagnosis |
| progression free survival | 5 years | Time period of progression survival from date of multiomics analysis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| response to antitumor treatment | 5 months | response according to RECIST v.1.1 criteria to antitumor treatment applied after multiomics analysis |
Countries
Germany
Contacts
Primary ContactRichard F Schlenk, M.D.
Outcome results
None listed